Latest News and Press Releases

Silver Spring, Md., May 29, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for...

EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June...

LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- TREOS Bio, a clinical-stage biotechnology company developing next-generation off-the-shelf peptide cancer immunotherapies, supported by biomarker-guided...

UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapyTGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that...

Orphan Drug Designation confers regulatory, financial and strategic advantagesEO2463 has shown potentially disease modifying activity in clinical testing in watch-and-wait iNHL patientsEO2463 has...

UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapyTGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that...

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

Liver disease is often found late because people have no symptoms. This research shows how using existing NHS blood test data could help change that.

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...

STORM Therapeutics announces that a subset analysis of sarcoma patients enrolled in the Phase 1 dose escalation study of STC-15 will be presented at ASCO.